復星醫藥(02196.HK)半年度實現淨利17.15億元 同比增長13.10%
格隆匯 8 月 25日丨復星醫藥(02196.HK)發佈2020年半年度報告，報告期內，集團實現營業收入140.28億元(人民幣，下同)，較2019年同期略有1.02%的下降。其中：藥品製造與研發業務實現營業收入100.12億元，較2019年同期減少8.11%；醫療器械與醫學診斷業務實現營業收入26.41億元，較2019年同期增長46.96%；醫療服務業務實現營業收入13.6億元，較2019年同期減少6.83%。一季度疫情因素對集團醫療服務業務、藥品製造與研發板塊注射劑業務等造成一定程度的影響，隨着有序復工復產，二季度各項生產經營已恢復，二季度當季實現營業收入81.48億元，較一季度環比增長38.55%，較2019年二季度同比增長9.47%。
報告期內，集團在中國大陸實現營業收入99.57億元，在其他國家或地區實現營業收入摺合人民幣40.71億元，其他國家或地區收入佔比為29.02%。
報告期內，集團實現歸屬於上市公司股東淨利潤17.15億元，歸屬於上市公司股東的扣除非經常性損益的淨利潤13.04億元，分別較2019年同期增長13.10%和11.71%，利潤增長主要來自於：(1)新型冠狀病毒核酸檢測試劑盒、負壓救護車及呼吸機等抗疫產品的貢獻；(2)核心產品非布司他片(優立通)、匹伐他汀鈣片(邦之)、草酸艾司西酞普蘭(啟程)等收入保持高速增長，人用狂犬疫苗銷量大幅提升；利妥昔單抗注射液(漢利康)新增生產規模(2000L)獲批後銷量快速提升，上半年實現收入2.24億元，6月當月收入突破億元；(3)受益於法規市場的需求，控股子公司Gland Pharma保持快速增長。
上半年，集團歸屬於上市公司股東淨利潤的增長幅度高於營業收入增幅的主要原因：(1)本期毛利率減去銷售費用率同比有2.4個百分點的提升；(2)本期利潤增長主要來自於持股比例較高的控股子公司增長貢獻；(3)利息支出同比減少；(4)收購Breas、復鋭醫療科技(Sisram)部分少數股權的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
